Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1703057 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $5.69Day +5.57%Mkt cap $1.6B1Y +24.5%Off 52W high −32.6%Vol (1Y) 75.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,410 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest14.8% of sh out |
| Days to cover7.0d |
| 13F net flow (QoQ)+5.25% |
| Top-10 13F concentration73.6% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$79.2M |
| Earnings (TTM)-$144.0M |
| ROE−14.5% |
| Net margin−194.9% |
| ROIC−19.7% |
| Sales growth 3Y−46.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+66.4% |
| 1Y+24.5% |
| 3Y−26.4% |
| 5Y−62.5% |
| Since incept. (ann.)−34.0% |
Total return through 2026-07-30 · series begins 2020-12-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)75.9% |
| Ann. volatility (3Y)68.9% |
| Sharpe (1Y)0.63 |
| Sharpe (3Y)0.19 |
| Max drawdown (1Y)−54.9% |
| Max drawdown (3Y)−75.0% |
| Beta (3Y vs SPY)2.43 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 30.3M | $106M | 9.99% | +10.0% |
| Capital World Investors | 13.4M | $47M | 4.41% | +0.0% |
| TWO SIGMA INVESTMENTS, LP | 10.6M | $37M | 3.48% | +81.8% |
| TD Waterhouse Canada Inc. | 9.6M | $34M | 3.15% | +42576.5% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 7.6M | $26M | 2.50% | −3.8% |
| UBS Group AG | 4.2M | $15M | 1.39% | +117.0% |
| ArrowMark Colorado Holdings LLC | 4.1M | $14M | 1.35% | +0.0% |
| BlackRock, Inc. | 4.0M | $14M | 1.33% | +4.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.14 | — | $8.3M | +96.3% |
| 2025-12-31 | 2026-02-24 | — | — | $44.9M | +788.4% |
| 2025-09-30 | 2025-11-06 | −$0.19 | — | $9.0M | +37.6% |
| 2025-06-30 | 2025-08-07 | −$0.12 | — | $17.1M | +133.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
CA 85% · US 15%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
